Resources Library by ANA

eHealth

This paper shows how with the aid of seven central questions, the potential success of ‘eHealth’ (the sale of medicines over the internet) can be ascertained and implications deduced for marketing. A survey of doctors, pharmacists and...

Catalogue: ESOMAR Congress 2000: The Impact Of Networking

Author: Harald Hasselmann

Company: Ipsos MRBI

September 1, 2000

Understanding the prescribing decision

By understanding the role that patient factors play in the prescribing decision, pharmaceutical marketers will be better able to understand the behavior of their customers and in turn be better able to market their products to their...

Catalogue: ESOMAR Global Healthcare 2002

Author: David A. Luery

Company: KANTAR TNS Malaysia

June 15, 2000

Service quality evaluation in the pharmaceutical industry (Spanish)

The use of this methodology allows us to draw' a performance chart of ourselves as well as of competitors identifying the strong cores of services that are to be maintained the weak cores that need to be improved and those others of a more...

Catalogue: Latin America 1999: Marketing In Latin America In The 21st Century

Authors: Nestor Cohen, Monica Soto

June 15, 1999

Service quality evaluation in the pharmaceutical industry

The use of this methodology allows us to draw' a performance chart of ourselves as well as of competitors identifying the strong cores of services that are to be maintained the weak cores that need to be improved and those others of a more...

Catalogue: Latin America 1999: Marketing In Latin America In The 21st Century

Authors: Nestor Cohen, Monica Soto

June 15, 1999

Information is power

This paper traces the evolution of the marketing research function within what is now Knoll Pharmaceuticals and what was, until April 1995 Boots Pharmaceuticals. It draws on relevant experiences over the last sixteen years to illustrate the central...

Catalogue: EphMRA/ESOMAR Conference 1997: Sharpening Tools For The Future

Authors: Catherine Ayland, Anne Marshall

June 15, 1997

From market research to marketing research and development

The world’s top ten pharmaceutical companies continue to reorient their strategies toward greater focus on core therapeutic segments and continuous improvement of efficiency in the development and marketing of their new chemical entities (NCE)....

Catalogue: EphMRA/ESOMAR Conference 1997: Sharpening Tools For The Future

Authors: Kenneth G. Watson, Andre Boer

June 15, 1997

Is there life after death?

When a company is developing several important new compounds and one is facing challenges in formulation development, it is important to establish whether the potential for the product with an alternative formulation would be viable in sales terms....

Catalogue: EphMRA/ESOMAR Conference 1997: Sharpening Tools For The Future

Authors: Alan J. Bowditch, Lorna Tuersley

June 15, 1997

Conjoint analysis

This paper begins by discussing the components of a conjoint paradigm and the alternatives within each. This is done to introduce a discussion of three issues: the concept of a “best” paradigm, the use of preference share as a predictor of...

Catalogue: EphMRA/ESOMAR Conference 1997: Sharpening Tools For The Future

Author: Roger Brice

June 15, 1997

The perception of new clinical entities

The most crucial time for close co-operation between clinical research and marketing research is during phase II and early phase III of clinical development. In these phases of development it is necessary to compare the new substance with similar...

Catalogue: EphMRA/ESOMAR Conference 1997: Sharpening Tools For The Future

Authors: Raf De Wilde, Barbel Matiaske

June 15, 1997